Intas Pharmaceuticals Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
30 Pages - GLDATA51018
$250.00

Summary

Intas Pharmaceuticals Ltd. (Intas) is a vertically integrated pharmaceutical company. It develops, manufactures, and markets pharmaceutical and biotechnology products for the treatment of a wide range of diseases including cardiovascular, diabetes, gynecology, infertility, respiratory disorders, gastroenterology, and pain management among others. The company’s offers products such as Intas include sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen among others. It also develops recombinant DNA protein (rDNA) products and plasma derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma derived product based therapies. The company markets products for the livestock, companion animals, equine, swine and poultry. Its manufacturing facilities include seven formulation manufacturing facilities and two API and Intermediate Facilities in India, one in Mexico and a packaging facility in the UK. The company markets its products in over 70 countries throughout the worldwide through internal sales force and a network of distributors. Intas is headquartered in Ahmedabad, Gujrat, India.

Intas Pharmaceuticals Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Intas Pharmaceuticals Ltd., Medical Devices Deals, 2010 to YTD 2016 10
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Intas Pharma Acquires Hospital Business of Combino Pharm 12
Intas Pharma Acquires Worldwide Rights To Metoprolol Succinate From Orbus Pharma 13
Private Equity 14
Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 14
ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For US$56.1 Million 16
ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For US$56 Million 17
Partnerships 18
Gedeon Richter Enters Into Research Agreement With Astron Research 18
Licensing Agreements 19
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 19
Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 20
AstraZeneca Enters Into Licensing Agreement With Intas Pharma 21
Amarillo Biosciences Enters Into Licensing Agreement With Intas Pharma 22
Equity Offering 24
Intas Pharma Files Registration Statement For IPO To Raise Up To US$200 Million 24
Intas Pharmaceuticals Ltd. - Key Competitors 26
Key Employees 27
Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Intas Pharmaceuticals Ltd., Deals By Therapy Area, 2010 to YTD 2016 8
Intas Pharmaceuticals Ltd., Medical Devices Deals, 2010 to YTD 2016 10
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Intas Pharma Acquires Hospital Business of Combino Pharm 12
Intas Pharma Acquires Worldwide Rights To Metoprolol Succinate From Orbus Pharma 13
Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 14
ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For US$56.1 Million 16
ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For US$56 Million 17
Gedeon Richter Enters Into Research Agreement With Astron Research 18
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 19
Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 20
AstraZeneca Enters Into Licensing Agreement With Intas Pharma 21
Amarillo Biosciences Enters Into Licensing Agreement With Intas Pharma 22
Intas Pharma Files Registration Statement For IPO To Raise Up To US$200 Million 24
Intas Pharmaceuticals Ltd., Key Competitors 26
Intas Pharmaceuticals Ltd., Key Employees 27
Intas Pharmaceuticals Ltd., Other Locations 28
Intas Pharmaceuticals Ltd., Subsidiaries 29

List of Figures
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Intas Pharmaceuticals Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Intas Pharmaceuticals Ltd., Medical Devices Deals, 2010 to YTD 2016 10

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838